 By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update TRANQUILITY Readout Possible in 4Q20 BioXcel Therapeutics, Inc. NASDAQ:BTAI is currently conducting the Phase 1b2 TRANQUILITY clinical trial of BXCL501 for the acute treatment of agitation in patients with dementia, including Alzheimers disease AD. The multicenter, randomized, double blind, placebo 